



Figure S3. Galunisertib and anti-PD-1 dual treatment increases PD-L1 expression and promotes healthy weight gain

(A) Pdx1-Cre x LSL-KRAS^{G12D} x LSL-TP53^{R172H} (KPC) mice were regenerated as a model of aggressive PDAC. At 6 weeks of age, mice were administered intraperitoneal injection every other day either a PBS vehicle (Control), 75 mg/kg of the TGFBR1 inhibitor Galunisertib, 200 μ g of an anti-PD-1 neutralizing antibody (anti-PD-1), or a combination of Galunisertib and anti-PD-1. At the conclusion of the study, tissues were collected and stained for PD-L1 by immunohistochemistry. **(B)** Mean increase in body weight from mice across all treatment groups displayed \pm S.E.M.